PlainPharmaWatch

CMS Open Payments · Program Year 2024

OMNIlife science, Inc

OMNIlife science, Inc reported $5,815,064.02 across General Payments, Research, and Ownership to 829 physicians and teaching hospitals across 865 transactions.

See the rankings → How this is sourced
$5.8M Top quartile payer
All-tracks total
865 Above-median volume
Transactions
829 Above-median reach
Recipients
+$395.4K
General Payments vs PY2023

OMNIlife science, Inc reported $5,815,064.02 across all CMS Open Payments tracks (General + Research + Ownership) to 829 physicians and teaching hospitals in Program Year 2024 - ranking #251 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,696,724.54, averaging $7.0K per recipient.

How OMNIlife science, Inc's $5.8M all-tracks total breaks down

OMNIlife science, Inc's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

40/100

Total payments

D

64/100

Transaction volume

F

16/100

Physician reach

F

16/100

Payment type diversity

D

63/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer omnilife-science-inc OMNIlife science, Inc

$5.8M · #251/1,925 · 0.0% industry · PY2024

  • TOT $5.8M
  • RANK #251
  • SHARE 0.0%
  • TXN 865
  • RCP 829
  • CAT 5
  • GEN $1.7M
  • ΔGEN +$395.4K
  • TOP1 30.4%
  • PY 2024

Volume peers

Nearest volume peer: AxioMed LLC ($5.8M)

Ipsen Innovation$5.8MOMNIlife science, Inc (this)$5.8MAxioMed LLC$5.8MLinvatec Corporation$5.8MHighridge Medical LLC$5.8M
All-tracks payment totals near OMNIlife science, Inc (CMS Open Payments PY2024)

OMNIlife science, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

OMNIlife science, Inc's CMS-reported General Payments increased by $395.4K (+30.4%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: OMNILIFE SCIENCE, INCPY2023: OMNILIFE SCIENCE, INCPY2024: OMNIlife science, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.3MPY2024$1.7M
PY2023
$1,301,282.87
PY2024
$1,696,724.54

What the Data Shows for OMNIlife science, Inc

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For OMNIlife science, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

"Royalty or License" leads the 5-category general-payment breakdown below at $1.4M (83.9% of General Payments, 43 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Royalty or License" leads OMNIlife science, Inc's 5-category general-payment breakdown at $1.4M, 83.9% of the reported total.

OMNIlife science, Inc reports 5 general-payment categories - the top three are Royalty or License (83.9%), Consulting Fee (12.1%), and Food and Beverage (1.7%). The remaining 2 categories make up 2.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How OMNIlife science, Inc divides its payments

General-payment categories, ordered by reported total

1. Royalty or License$1.4M2. Consulting Fee$205.0K3. Food and Beverage$28.5K4. Travel and Lodging$20.0K5. Grant$20.0K
Payment Type Amount Transactions
Royalty or License $1.4M 43
Consulting Fee $205.0K 91
Food and Beverage $28.5K 602
Travel and Lodging $20.0K 91
Grant $20.0K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,324,381.55 (78.1%) of $1,696,724.54 in this company's General Payments records across 158 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for OMNIlife science, Inc

The five named recipients with the highest reported General Payments from this company

Massachusetts General Hospit…$516.0KStefan Kreuzer$333.4KJan Koenig$232.7KVasili Karas$121.7KLinda Suleiman$120.7K
  1. 1

    Massachusetts General Hospital

    $516,007.61 across 6 reported transactions

  2. 2

    Stefan Kreuzer

    $333,351.70 across 41 reported transactions

  3. 3

    Jan Koenig

    $232,680.00 across 3 reported transactions

  4. 4

    Vasili Karas

    $121,664.17 across 67 reported transactions

  5. 5

    Linda Suleiman

    $120,678.07 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

OMNIlife science, Inc ranks #251 of 1,925 by total payments (top 13% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #825 of 1,838 by HHI (top 45% most concentrated), a wider distribution than most similarly sized payers.

019.238.357.576.71641.81653.71665.51677.31689.2Total payments ($M)Concentration (HHI, 0-10,000)
OMNIlife science, Inc (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as OMNIlife science, Inc's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OMNIlife science, Inc.

Takeda Pharmaceuticals U.S.A., Inc.

HHI 1650

Merck Healthcare KGaA

HHI 1648

Southern Implants North America Inc

HHI 1661

Aesculap Implant Systems, LLC

HHI 1647

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with OMNIlife science, Inc.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

OMNIlife science, Inc ranks #251 of 1,925 by all-tracks total payments, led by "Royalty or License".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download OMNIlife science, Inc's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.